An Interventional Study of Infigratinib in Children With Hypochondroplasia
Part of paid clinical trials in Oakland, California.
- Sponsor
- QED Therapeutics, a BridgeBio company
- Study ID
- NCT06873035
- Phase
- PHASE2/PHASE3
- Status
- Enrolling By Invitation
Conditions
- Hypochondroplasia
Eligibility Criteria
- Sex
- ALL
- Age
- 3 Years - 18 Years
- Healthy Volunteers
- Not accepted
Interventions
- infigratinib 0.128 mg/kg/day — DRUGOral infigratinib 0.128 mg/kg/day
- infigratinib 0.25 mg/kg/day — DRUGOral infigratinib 0.25 mg/kg/day
Study Details
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses, who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).
Key Dates
- First listed
- Mar 12, 2025
- Start date
- Apr 22, 2025
- Status verified
- May 2026
- Primary completion
- Jan 31, 2027
- Completion
- Jan 31, 2027
Study Design
- Enrollment
- 24 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase 2 Cohort 1Oral infigratinib 0.128 mg/kg/day
- Experimental: Phase 2 Cohort 2Oral infigratinib 0.25 mg/kg/day
Primary Outcome Measure
Change from baseline (BL) in Annualized Height Velocity (AHV; cm/year) [ Time Frame: 26 weeks ]
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UCSF Benioff Children's Hospital | Oakland | California | 94609 | - |
| Childrens Hospital Colorado | Aurora | Colorado | 80045 | - |
| Children's National Hospital | Washington D.C. | District of Columbia | 20010 | - |
| Johns Hopkins School of Medicine | Baltimore | Maryland | 21287 | - |
| University of Missouri | Columbia | Missouri | 65201 | - |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | - |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | - |
| University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic | Madison | Wisconsin | 53705 | - |
Find similar trials in Oakland, CA
Related Studies
- A Multicenter Multinational Observational Study of Children With HypochondroplasiaRecruiting · BioMarin Pharmaceutical · Phoenix, Arizona
- Prospective Clinical Assessment Study in Children With HypochondroplasiaRecruiting · QED Therapeutics, a BridgeBio company · Oakland, California
- Long-Term Extension Study of Vosoritide to Treat Children With HypochondroplasiaPHASE3 · Enrolling By Invitation · BioMarin Pharmaceutical · Wilmington, Delaware
- A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsPHASE2 · Recruiting · BioMarin Pharmaceutical · Phoenix, Arizona